Get the Stockscreener App
9.99
0.44%
-0.04
Iteos Therapeutics Inc stock is traded at $9.99, with a volume of 1.25M.
It is down -0.44% in the last 24 hours and up +37.74% over the past month.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
See More
Previous Close:
$10.03
Open:
$10
24h Volume:
1.25M
Relative Volume:
1.13
Market Cap:
$382.13M
Revenue:
$127.70M
Net Income/Loss:
$-121.25M
P/E Ratio:
-3.1714
EPS:
-3.15
Net Cash Flow:
$-120.32M
1W Performance:
+16.66%
1M Performance:
+37.74%
6M Performance:
+16.80%
1Y Performance:
-41.77%
1-Day Range:
$9.85
$10.06
1-Week Range:
$8.30
$11.35
52-Week Range:
$4.80
$18.13
Iteos Therapeutics Inc Stock (ITOS) Company Profile
Name
Iteos Therapeutics Inc
Sector
Industry
Phone
857-204-4583
Address
321 ARSENAL STREET, WATERTOWN
Compare ITOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITOS
Iteos Therapeutics Inc
|
9.985 | 332.60M | 127.70M | -121.25M | -120.32M | -3.15 |
|
ONC
Beone Medicines Ltd Adr
|
245.77 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.41 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.32 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.93 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.40 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-14-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-13-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-13-24 | Initiated | Wells Fargo | Overweight |
| May-05-21 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | SVB Leerink | Outperform |
| Aug-18-20 | Initiated | Wedbush | Outperform |
View All
Iteos Therapeutics Inc Stock (ITOS) Latest News
iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Rx Rundown: Novartis, iTeos Therapeutics, Moderna and more - Medical Marketing and Media
iTeos Therapeutics Stock Jumps Following Operational Closure Announcement - MSN
All Over For iTeos But Applause For Plan To Return Cash Fast - insights.citeline.com
iTeos Therapeutics (NASDAQ:ITOS) Receives “Equal Weight” Rating from Wells Fargo & Company - Defense World
iTeos Therapeutics to wind down operations, explore asset sales By Investing.com - Investing.com South Africa
iTeos Therapeutics (NASDAQ:ITOS) Lowered to “Neutral” Rating by Wedbush - Defense World
Wedbush cuts iTeos stock rating, raises PT to $12 from $10 - Investing.com Canada
Cancer drugmaker iTeos to shut down - BioPharma Dive
iTeos Therapeutics To Wind Down Operations, Explores Asset Sale: Retail Believes It’s ‘Worth More Selling It Off’ - Investing.com India
iTeos Therapeutics stock surges on wind-down news By Investing.com - Investing.com Canada
Watertown immuno-oncology biotech winds down operations - The Business Journals
iTeos Therapeutics (ITOS) Downgraded by Wells Fargo with Revised Price Target | ITOS Stock News - GuruFocus
iTeos Therapeutics (ITOS) Faces Downgrade Amid Operational Changes | ITOS Stock News - GuruFocus
ITeos Therapeutics (ITOS) Sees Downgrade and Target Price Cut | - GuruFocus
ITeos Therapeutics (ITOS) Sees Downgrade and Target Price Cut | ITOS Stock News - GuruFocus
ITeos Therapeutics (ITOS) Receives Analyst Downgrade from Wedbus - GuruFocus
iTeos Therapeutics (ITOS) Downgraded as Company Plans Operationa - GuruFocus
Wedbush Downgrades iTeos Therapeutics (ITOS) Rating to Neutral | - GuruFocus
I Teos Therapeutics Inc Expected Severance Costs Of $21.8 Million To $24.7 Million - marketscreener.com
Wedbush Downgrades iTeos Therapeutics to Neutral From Outperform, Adjusts Price Target to $12 From $10 - marketscreener.com
iTeos Therapeutics (ITOS) Shares Surge on Plans to Cease Operati - GuruFocus
Drug developer iTeos to shut down operations after cancer therapy setback - whbl.com
iTeos Therapeutics (ITOS) to Cease Operations and Explore Strategic Options - GuruFocus
iTeos Therapeutics (ITOS) to Wind Down Operations, Focus on Shar - GuruFocus
Drug developer iTeos winds down after cancer therapy setback - marketscreener.com
iTeos Therapeutics Announces Strategic Wind Down Plan - TipRanks
ITeos Therapeutics to Wind Down Operations - marketscreener.com
iTeos stock surges on plans to end operations (ITOS:NASDAQ) - Seeking Alpha
iTeos Therapeutics to wind down operations, explore asset sales - Investing.com
iTeos Therapeutics Announces Its Intention to Wind Down Operations - GlobeNewswire
iTeos Therapeutics Announces Intent to Wind Down Operations and Explore Asset Sales to Maximize Shareholder Value - Nasdaq
ITeos plans to shut down operations after cancer therapy setback - marketscreener.com
iTeos plans to shut down operations after cancer therapy setback - TradingView
iTeos Therapeutics Winds Down Operations: Key Assets EOS-984 and EOS-215 Up for Sale - Stock Titan
D. E. Shaw & Co. Inc. Cuts Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Northern Trust Corp Acquires 7,881 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
60,079 Shares in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Purchased by BNP Paribas Financial Markets - Defense World
(ITOS) Trading Advice - news.stocktradersdaily.com
Balyasny Asset Management L.P. Buys Shares of 28,350 iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Q2 Earnings Forecast for ITOS Issued By Leerink Partnrs - Defense World
Q4 Earnings Forecast for ITOS Issued By Leerink Partnrs - Defense World
The week in pharma: action, reaction and insight – week to May 16 - The Pharma Letter
Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet - MSN
Research Analysts Issue Forecasts for ITOS Q2 Earnings - Defense World
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Receives $18.83 Average Target Price from Analysts - Defense World
iTeos Therapeutics (NASDAQ:ITOS) Rating Lowered to “Hold” at Leerink Partnrs - Defense World
Leerink Partners Reiterates “Market Perform” Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World
ITOS: ITeos Therapeutics Downgraded to Neutral by HC Wainwright & Co. | ITOS Stock News - GuruFocus
iTeos Therapeutics: End To Belrestotug Program Leads To A Hold Rating (NASDAQ:ITOS) - Seeking Alpha
Piper Sandler cuts iTeos stock price target to $12 from $16 - Investing.com Canada
Iteos Therapeutics Inc Stock (ITOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Iteos Therapeutics Inc Stock (ITOS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 10% Owner |
May 14 '25 |
Buy |
7.41 |
1,658,978 |
12,285,562 |
7,388,978 |
| GADICKE ANSBERT | Former 10% Owner |
May 13 '25 |
Sale |
8.06 |
1,031,931 |
8,317,364 |
3,452,797 |
| MPM BIOVENTURES 2018, L.P. | Former 10% Owner |
May 13 '25 |
Sale |
8.06 |
630,191 |
5,079,339 |
2,108,594 |
| MPM BioVentures 2014, L.P. | Former 10% Owner |
May 13 '25 |
Sale |
8.06 |
630,191 |
5,079,339 |
2,108,594 |
| Van Hauwermeiren Timothy | Director |
May 13 '25 |
Option Exercise |
4.30 |
22,346 |
96,088 |
22,346 |
| Gall Matthew | Chief Financial Officer |
Nov 19 '24 |
Buy |
7.73 |
5,000 |
38,635 |
65,429 |
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):